Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Annexon Biosciences (ANNX)
NASDAQ:ANNX
RESEARCH TOOLSreports
ANNX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.64 - $8.40
Previous CloseN/A
Volume252.73K
Average Volume (3M)1.43M
Market Cap
$287.80M
Enterprise Value$517.89M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.48
Next Earnings
Mar 20, 2025EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.04
Shares Outstanding106,593,506
10 Day Avg. Volume1,197,834
30 Day Avg. Volume1,434,013
Standard Deviation0.26
R-Squared0.04
Alpha-0.00998
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)179.88
Price to Cash Flow (P/CF)-2.30
P/FCF Ratio0.00
Enterprise Value/Market Cap1.80
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-158.52
Enterprise Value/Ebitda-4.00
Forecast
1Y Price Target
$18.00Price Target Upside531.58% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
Annexon Biosciences News
PremiumCompany Announcements
Annexon Biosciences Strengthens Board for Strategic Growth
PremiumCompany Announcements
Annexon Biosciences Reports Q3 Financial Results---
Bulls Say, Bears Say
Bulls Say
Efficacy And Treatment ImpactANX005 treated patients experienced a significant improvement in muscle score, indicating a potential for future recovery not typically seen with standard care.
Market PositioningExperts think ANX005 could become the new standard of care for Guillain-Barre Syndrome.
Bears Say
Regulatory ChallengesANX005 patients successfully 'matched' to global registry patients treated with standard-of-care, which is an important regulatory requirement for potential ANX005 approval.
---
Ownership Overview
13.86% Insiders
16.25% Mutual Funds
0.51% Other Institutional Investors
44.86% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ANNX FAQ
What was Annexon Biosciences’s price range in the past 12 months?
Annexon Biosciences lowest stock price was $2.63 and its highest was $8.40 in the past 12 months.
What is Annexon Biosciences’s market cap?
Annexon Biosciences’s market cap is $287.80M.
When is Annexon Biosciences’s upcoming earnings report date?
Annexon Biosciences’s upcoming earnings report date is Mar 20, 2025 which is in 27 days.
How were Annexon Biosciences’s earnings last quarter?
Annexon Biosciences released its earnings results on Nov 14, 2024. The company reported -$0.25 earnings per share for the quarter, beating the consensus estimate of -$0.258 by $0.008.
Is Annexon Biosciences overvalued?
According to Wall Street analysts Annexon Biosciences’s price is currently Undervalued.
Does Annexon Biosciences pay dividends?
Annexon Biosciences does not currently pay dividends.
What is Annexon Biosciences’s EPS estimate?
Annexon Biosciences’s EPS estimate is -0.27.
How many shares outstanding does Annexon Biosciences have?
Annexon Biosciences has 106,593,506 shares outstanding.
What happened to Annexon Biosciences’s price movement after its last earnings report?
Annexon Biosciences reported an EPS of -$0.25 in its last earnings report, beating expectations of -$0.258. Following the earnings report the stock price went down -3.359%.
Which hedge fund is a major shareholder of Annexon Biosciences?
Currently, no hedge funds are holding shares in ANNX
---
Annexon Biosciences Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$18.00 (531.58% Upside)
$18.00 (531.58% Upside)
Blogger Sentiment
Bullish
ANNX Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $126.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.6%
Last 30 Days ▼ 8.1%
Last 30 Days ▼ 8.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-44.44%
12-Months-Change
Fundamentals
Return on Equity
-48.12%
Trailing 12-Months
Asset Growth
85.84%
Trailing 12-Months
Company Description
Annexon Biosciences
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005; ANX007; and ANX009.
---
ANNX Stock 12 Month Forecast
Average Price Target
$18.00
▲(531.58% Upside)
Technical Analysis
Alnylam Pharma
―
Ionis Pharmaceuticals
―
Vertex Pharmaceuticals
―
Ultragenyx Pharmaceutical
―
Crispr Therapeutics AG
―
Best Analysts Covering ANNX
1 Year
1 Year Success Rate
4/23 ratings generated profit
1 Year Average Return
-30.20%
reiterated a buy rating 2 months ago
Copying Joseph Stringer's trades and holding each position for 1 Year would result in 17.39% of your transactions generating a profit, with an average return of -30.20% per trade.
---